Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 | P30531 | 2/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.41 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.41 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.41 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.41 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4908632 | 1.00 | SLC6A1 (0.41) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL4361686 | 1.00 | SLC6A1 (0.41) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL28863484 | 0.89 | SCN9A (0.43) | SLC6A1SLC6A11SLC6A13CHRNB2CHRNA4 | |
| SCHEMBL28241589 | 0.89 | SCN9A (0.43) | SLC6A1SLC6A11SLC6A13CHRNB2CHRNA4 | |
| SCHEMBL3444600 | 0.89 | SCN9A (0.43) | SLC6A1SLC6A11SLC6A13CHRNB2CHRNA4 | |
| SCHEMBL671201 | 0.88 | TDP1 (0.40) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| Tert-Butyl Formate SCHEMBL28132780 | 0.85 | TDP1 (0.36) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL795458 | 0.84 | KDM4E (0.37) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL27405696 | 0.81 | SLC6A1 (0.39) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL28168261 | 0.81 | GABRA5 (0.46) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7342016-B2 | Farnesyl protein transferase inhibitors as antitumor agents | SCHERING CORPORATION (US) | 2008-03-11 | — | — | US | disclosed |
| EP-1313725-B1 | TRICYCLIC ANTITUMOR COMPOUNDS BEING FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORP (US) | 2007-04-11 | — | — | EP | disclosed |
| EP-1140904-B1 | FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORP (US) | 2005-04-20 | — | — | EP | disclosed |
| US-6800636-B2 | FOR THERAPY OF CANCER | SCHERING CORPORATION | 2004-10-05 | — | — | US | disclosed |
| EP-1453513-A1 | USE OF FPT INHIBITORS AND AT LEAST TWO ANTINEOPLASTIC AGENTS IN THE TREATMENT OF CANCER | SCHERING CORPORATION (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20040122018-A1 | Novel farnesyl protein transferase inhibitors as antitumor agents | SCHERING CORPORATION | 2004-06-24 | — | — | US | disclosed |
| US-20040006087-A1 | Method of treating cancer using FPT inhibitors and antineoplastic agents | SCHERING CORPORATION | 2004-01-08 | — | — | US | disclosed |
| US-20030229099-A1 | Novel farnesyl protein transferase inhibitors as antitumor agents | PHARMACOPEIA DRUG DISCOVERY | 2003-12-11 | — | — | US | disclosed |
| WO-2003047586-A1 | USE OF FPT INHIBITORS AND AT LEAST TWO ANTINEOPLASTIC AGENTS IN THE TREATMENT OF CANCER | SCHERING CORPORATION (US) | 2003-06-12 | — | — | WO | disclosed |
| EP-1313725-A1 | TRICYCLIC ANTITUMOR COMPOUNDS BEING FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 2003-05-28 | — | — | EP | disclosed |
| US-20030040520-A1 | Farnesyl protein transferase inhibitors | GUZI TIMOTHY (US) | 2003-02-27 | — | — | US | disclosed |
| US-20020198216-A1 | Novel farnesyl protein transferase inhibitors as antitumor agents | PHARMACOPEIA DRUG DISCOVERY | 2002-12-26 | — | — | US | disclosed |
| US-6362188-B1 | ANTICANCER AGENTS | SCHERING CORPORATION | 2002-03-26 | — | — | US | disclosed |
| WO-2002018368-A1 | TRICYCLIC ANTITUMOR COMPOUNDS BEING FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 2002-03-07 | — | — | WO | disclosed |
| EP-1140904-A1 | FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000037458-A1 | FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 2000-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030040520-A1 | Farnesyl protein transferase inhibitors | FNTA, FNTB, CETP | SLC6A1 4552/4885GABRA5 4350/4885GABRB2 4474/4885 |
| US-20040006087-A1 | Method of treating cancer using FPT inhibitors and antineoplastic agents | NNT, FNTB, NNMT | SLC6A1 4174/4885GABRA5 4580/4885GABRB2 4274/4885 |
| US-20030229099-A1 | Novel farnesyl protein transferase inhibitors as antitumor agents | FNTA, FNTB, ACAT2 | SLC6A1 3572/4885GABRA5 4112/4885GABRB2 4058/4885 |
| US-20020198216-A1 | Novel farnesyl protein transferase inhibitors as antitumor agents | FNTB, FNTA, PTAR1 | SLC6A1 3667/4885GABRA5 4344/4885GABRB2 4271/4885 |
| US-20040122018-A1 | Novel farnesyl protein transferase inhibitors as antitumor agents | FNTA, FNTB, ACAT2 | SLC6A1 3561/4885GABRA5 4124/4885GABRB2 4078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.